CCDC169-SOHLH2: A Potential Drug Target and Biomarker (G100526761)

Target Name: CCDC169-SOHLH2

NCBI ID: G100526761

CCDC169-SOHLH2

CCDC169-SOHLH2: A Potential Drug Target and Biomarker

CDC169-SOHLH2 is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the SOHLH2 family, which is known for its role in the development and maintenance of neural stem cells. The SOHLH2 family has also been implicated in various diseases, including neurodegenerative disorders and cancer.

The search for new drug targets and biomarkers has led to the identification of CCDC169-SOHLH2 as a potential drug target. This protein has been shown to play a role in the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

CDC169-SOHLH2 and Neurodegenerative Disorders

Neurodegenerative disorders are a group of diseases that are characterized by the progressive loss of brain cells and their functions. These disorders include Alzheimer's disease, Parkinson's disease, Huntington's disease, and other forms of dementia.

CDC169-SOHLH2 has been shown to be involved in the development and progression of neurodegenerative disorders. Studies have shown that CCDC169-SOHLH2 is overexpressed in the brains of individuals with neurodegenerative disorders. This overexpression is thought to contribute to the progressive loss of brain cells and their functions that occurs in these disorders.

In addition, CCDC169-SOHLH2 has also been shown to play a role in the pathogenesis of neurodegenerative disorders. For example, studies have shown that CCDC169-SOHLH2 can cause neurotoxicity in the brain, which is thought to contribute to the development of neurodegenerative disorders.

CDC169-SOHLH2 and Cancer

Cancer is a group of diseases that are characterized by the uncontrolled growth and proliferation of cells. Cancer is a leading cause of death worldwide, and its incidence is expected to continue to increase in the future.

CDC169-SOHLH2 has also been shown to be involved in the development and progression of cancer. Studies have shown that CCDC169-SOHLH2 is overexpressed in various types of cancer, including breast, lung, and ovarian cancer. This overexpression is thought to contribute to the progressive growth and proliferation of cancer cells.

In addition, CCDC169-SOHLH2 has also been shown to play a role in the regulation of cell growth and differentiation. For example, studies have shown that CCDC169-SOHLH2 can cause cell cycle arrest in the G1 phase, which is thought to contribute to the regulation of cell growth and differentiation.

CDC169-SOHLH2 and Autoimmune Diseases

Autoimmune diseases are a group of diseases that are characterized by the immune system attacking the body's own tissues. These diseases include rheumatoid arthritis, lupus, and multiple sclerosis.

CDC169-SOHLH2 has also been shown to be involved in the development and progression of autoimmune diseases. Studies have shown that CCDC169-SOHLH2 is overexpressed in various tissues of individuals with autoimmune diseases. This overexpression is thought to contribute to the progressive damage to the body's own tissues that occurs in these diseases.

In addition, CCDC169-SOHLH2 has also been shown to play a role in the regulation of immune cell function. For example, studies have shown that CCDC169-SOHLH2 can

Protein Name: CCDC169-SOHLH2 Readthrough

Functions: Transcription regulator of both male and female germline differentiation. Suppresses genes involved in spermatogonial stem cells maintenance, and induces genes important for spermatogonial differentiation. Coordinates oocyte differentiation without affecting meiosis I (By similarity)

The "CCDC169-SOHLH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC169-SOHLH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets